Merchant Funds Management, page-24

TT,
It is a phase 1 / 2 trial, specifically targeting ASD / autism based on a number of Israeli studies that show the effectiveness of full spectrum cannabinoids (less than 0.3 % thc ) - the dolce strains should be more effective given higher levels of cbda , cbg, cbn , cbdb and p, - do you honestly think monash health with head of paediatric neurology would run a phase 1 and 2 trial without all dosage parameters in place -

From the NTI 5th May announcement:

"Commenting on the Study, A/Profressor Michael Fahey said:

It is exciting to undertake a properly planned and executed study on a novel CBD product.Many other studies do not have the rigor to ensure that the results are translatable to evidence based clinical treatments"

Your post is deliberately false and misleading, -- is it because of your apparent love /hate relationship with BL.